Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 6 (June)

1. Unintended consequences of caps on Medicare drug benefits.
   N Engl J Med, 354(22): 2349-59. [Abstract] [Full-text]
2. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation.
   J Neurosci, 26(22): 5881-7. [Abstract] [Full-text]
3. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.
   Am J Respir Crit Care Med, 173(11): 1270-5. [Abstract] [Full-text]
4. Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.
   Bioorg Med Chem Lett, 16(13): 3590-4. [Abstract] [Full-text]
5. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.
   Pediatrics, 117(6): 2132-7. [Abstract] [Full-text]
6. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.
   Pediatrics, 117(6): 2126-31. [Abstract] [Full-text]
7. Pediatric medication safety and the media: what does the public see?
   Pediatrics, 117(6): 1907-14. [Abstract] [Full-text]
8. Controlled dose delivery in topical treatment of anal fissure: pilot study of a new paradigm.
   Dis Colon Rectum, 49(6): 865-8. [Abstract] [Full-text]
9. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal.
   Lancet Oncol, 7(6): 515-6. [Abstract] [Full-text]
10. Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice.
    Eur J Pharmacol, 539(3): 195-204. [Abstract] [Full-text]
11. Target-mediated drug disposition and dynamics.
    Biochem Pharmacol, 72(1): 1-10. [Abstract] [Full-text]
12. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women.
    Clin Chim Acta, 369(1): 73-7. [Abstract] [Full-text]
13. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
    Biomaterials, 27(26): 4635-45. [Abstract] [Full-text]
14. Alginate-whey protein granular microspheres as oral delivery vehicles for bioactive compounds.
    Biomaterials, 27(26): 4646-54. [Abstract] [Full-text]
15. Treatment of metastatic breast cancer with vinorelbine and docetaxel.
    Am J Clin Oncol, 29(3): 276-80. [Abstract] [Full-text]
16. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Am J Clin Oncol, 29(3): 267-75. [Abstract] [Full-text]
17. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Am J Clin Oncol, 29(3): 246-51. [Abstract] [Full-text]
18. Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer.
    Am J Clin Oncol, 29(3): 240-5. [Abstract] [Full-text]
19. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    Am J Clin Oncol, 29(3): 232-9. [Abstract] [Full-text]
20. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
    Am J Clin Oncol, 29(3): 225-31. [Abstract] [Full-text]
21. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Cancer, 106(12): 2576-82. [Abstract] [Full-text]
22. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
    Cancer, 106(12): 2540-6. [Abstract] [Full-text]
23. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Cancer, 106(12): 2617-23. [Abstract] [Full-text]
24. Effects of transdermal testosterone administration on insulin sensitivity, fat mass and distribution, and markers of inflammation and thrombolysis in human immunodeficiency virus-infected women with mild to moderate weight loss.
    Fertil Steril, 85(6): 1794-802. [Abstract] [Full-text]
25. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer.
    Expert Rev Anticancer Ther, 6(6): 931-9. [Abstract] [Full-text]
26. First- and second-line therapy of metastatic colorectal cancer.
    Expert Rev Anticancer Ther, 6(6): 921-30. [Abstract] [Full-text]
27. Nonplatinum therapy in advanced bladder cancer.
    Expert Rev Anticancer Ther, 6(6): 887-94. [Abstract] [Full-text]
28. Systemic chemotherapy options for metastatic bladder cancer.
    Expert Rev Anticancer Ther, 6(6): 877-85. [Abstract] [Full-text]
29. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.
    Invest New Drugs, 24(5): 447-54. [Abstract] [Full-text]
30. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
    Invest New Drugs, 24(5): 413-21. [Abstract] [Full-text]
31. Photodynamic therapy of subfoveal choroidal neovascularization secondary to reticular pattern dystrophy: three-year results of an uncontrolled, prospective case series.
    Am J Ophthalmol, 141(6): 1152-4. [Abstract] [Full-text]
32. A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis.
    Am J Cardiol, 97(12): 1685-90. [Abstract] [Full-text]
33. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies.
    J Pediatr Oncol Nurs, 23(4): 176-81. [Abstract] [Full-text]
34. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures.
    J Clin Epidemiol, 59(7): 739-46. [Abstract] [Full-text]
35. Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients.
    Pediatr Blood Cancer, 47(2): 147-51. [Abstract] [Full-text]
36. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia.
    Pediatr Blood Cancer, 47(2): 206-9. [Abstract] [Full-text]
37. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.
    Arch Ophthalmol, 124(6): 815-23. [Abstract] [Full-text]
38. Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke.
    Neurology, 66(11): 1745-6. [Abstract] [Full-text]
39. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample.
    Neurology, 66(11): 1742-4. [Abstract] [Full-text]
40. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Neurology, 66(11): 1661-7. [Abstract] [Full-text]
41. Emerging endoluminal therapies for gastroesophageal reflux disease: adverse events.
    Am J Surg, 192(1): 72-5. [Abstract] [Full-text]
42. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
    Int J Cancer, 119(2): 423-31. [Abstract] [Full-text]
43. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
    Int J Cancer, 119(2): 309-16. [Abstract] [Full-text]
44. Comparison of two fluid-management strategies in acute lung injury.
    N Engl J Med, 354(24): 2564-75. [Abstract] [Full-text]
45. Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management.
    Am Heart J, 151(6): S17-23. [Abstract] [Full-text]
46. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Gynecol Oncol, 102(1): 32-40. [Abstract] [Full-text]
47. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children.
    Clin Infect Dis, 43(2): 243-52. [Abstract] [Full-text]
48. Insulin pump therapy and health-related quality of life in children and adolescents with type 1 diabetes.
    J Pediatr Psychol, 31(6): 650-60. [Abstract] [Full-text]
49. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
    J Clin Oncol, 24(18): 2903-9. [Abstract] [Full-text]
50. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
    J Clin Oncol, 24(18): 2891-6. [Abstract] [Full-text]
51. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
    J Clin Oncol, 24(18): 2879-84. [Abstract] [Full-text]
52. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    J Clin Oncol, 24(18): 2828-35. [Abstract] [Full-text]
53. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    J Clin Oncol, 24(18): 2786-92. [Abstract] [Full-text]
54. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    J Clin Oncol, 24(18): 2757-64. [Abstract] [Full-text]
55. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
    J Clin Oncol, 24(18): 2750-6. [Abstract] [Full-text]
56. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    J Clin Oncol, 24(18): 2715-22. [Abstract] [Full-text]
57. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    J Clin Oncol, 24(18): 2707-14. [Abstract] [Full-text]
58. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.
    Lancet, 367(9527): 1981-9. [Abstract] [Full-text]
59. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    J Clin Oncol, 24(18): 2866-72. [Abstract] [Full-text]
60. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    J Clin Oncol, 24(18): 2773-8. [Abstract] [Full-text]
61. Drug-eluting stent restenosis the pattern predicts the outcome.
    J Am Coll Cardiol, 47(12): 2399-404. [Abstract] [Full-text]
62. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
    Br J Ophthalmol, 90(7): 869-74. [Abstract] [Full-text]
63. Retinoic acid and ascorbic acid act synergistically in inhibiting human breast cancer cell proliferation.
    J Nutr Biochem, 17(7): 454-62. [Abstract] [Full-text]
64. Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model.
    Cancer Lett, 238(2): 197-201. [Abstract] [Full-text]
65. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Biomaterials, 27(28): 4975-83. [Abstract] [Full-text]
66. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.
    CMAJ, 174(13): 1847-52. [Abstract] [Full-text]
67. Photocleavage of o-nitrobenzyl ether derivatives for rapid biomedical release applications.
    Bioorg Med Chem Lett, 16(15): 4007-10. [Abstract] [Full-text]
68. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
    J Natl Cancer Inst, 98(12): 839-45. [Abstract] [Full-text]
69. How conducting a clinical trial affects physicians' guideline adherence and drug preferences.
    JAMA, 295(23): 2759-64. [Abstract] [Full-text]
70. Prescribing to older ED patients.
    Am J Emerg Med, 24(4): 468-78. [Abstract] [Full-text]
71. Older patients presenting to a county hospital ED after a fall: missed opportunities for prevention.
    Am J Emerg Med, 24(4): 413-7. [Abstract] [Full-text]
72. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease.
    Am J Epidemiol, 164(1): 56-62. [Abstract] [Full-text]
73. PTSD, depression, prescription drug use, and health care utilization of Chinese workers affected by the WTC attacks.
    J Immigr Minor Health, 8(3): 203-10. [Abstract] [Full-text]
74. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.
    Br J Surg, 93(7): 872-8. [Abstract] [Full-text]
75. Facilitation of neonatal endotracheal intubation with mivacurium and fentanyl in the neonatal intensive care unit.
    Arch Dis Child Fetal Neonatal Ed, 91(4): F279-82. [Abstract] [Full-text]
76. Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death.
    Radiology, 240(1): 145-51. [Abstract] [Full-text]
77. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
    Arterioscler Thromb Vasc Biol, 26(7): 1660-6. [Abstract] [Full-text]
78. Quality of life and hormone use: new validation results of MRS scale.
    Health Qual Life Outcomes, 4: 32. [Abstract] [Full-text]
79. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion.
    AAPS PharmSciTech, 7(2): E55. [Abstract] [Full-text]
80. Retroperitoneal sarcomas: Combined-modality treatment approaches.
    J Surg Oncol, 94(1): 81-7. [Abstract] [Full-text]
81. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1120-8. [Abstract] [Full-text]
82. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1106-11. [Abstract] [Full-text]
83. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1165-9. [Abstract] [Full-text]
84. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
    Int J Radiat Oncol Biol Phys, 65(4): 1036-44. [Abstract] [Full-text]
85. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
    Stroke, 37(7): 1822-7. [Abstract] [Full-text]
86. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
    Stroke, 37(7): 1798-804. [Abstract] [Full-text]
87. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Stroke, 37(7): 1810-5. [Abstract] [Full-text]
88. Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats.
    Stroke, 37(7): 1888-94. [Abstract] [Full-text]
89. Intravenous versus combined (intravenous and intra-arterial) thrombolysis in acute ischemic stroke: a transcranial color-coded duplex sonography--guided pilot study.
    Stroke, 37(7): 1805-9. [Abstract] [Full-text]
90. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
    Stroke, 37(7): 1917-22. [Abstract] [Full-text]
91. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.
    J Med Virol, 78(8): 1003-10. [Abstract] [Full-text]
92. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort.
    Am J Public Health, 96(7): 1219-25. [Abstract] [Full-text]
93. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection, 1990-2002.
    Pediatr Infect Dis J, 25(7): 628-33. [Abstract] [Full-text]
94. Application of encapsulated cell technology for retinal degenerative diseases.
    Expert Opin Biol Ther, 6(7): 717-26. [Abstract] [Full-text]
95. Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
    Expert Opin Biol Ther, 6(7): 699-708. [Abstract] [Full-text]
96. Controlled release of fibroblast growth factor-2 from an injectable 6-O-desulfated heparin hydrogel and subsequent effect on in vivo vascularization.
    J Biomed Mater Res A, 78(2): 364-71. [Abstract] [Full-text]
97. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    J Clin Oncol, 24(19): 3157-63. [Abstract] [Full-text]
98. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
    J Clin Oncol, 24(19): 3142-9. [Abstract] [Full-text]
99. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    J Clin Oncol, 24(19): 3061-8. [Abstract] [Full-text]
100. A meta-analysis of the association between adherence to drug therapy and mortality.
     BMJ, 333(7557): 15. [Abstract] [Full-text]
101. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
     J Clin Oncol, 24(19): 3048-55. [Abstract] [Full-text]
102. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
     J Clin Oncol, 24(19): 3013-8. [Abstract] [Full-text]
103. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
     J Clin Oncol, 24(19): 3121-7. [Abstract] [Full-text]
104. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
     J Clin Oncol, 24(19): 3128-35. [Abstract] [Full-text]
105. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
     J Clin Oncol, 24(19): 3150-6. [Abstract] [Full-text]
106. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
     J Clin Oncol, 24(19): 3026-31. [Abstract] [Full-text]
107. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients--effects of antiretroviral therapy.
     J Acquir Immune Defic Syndr, 42(3): 277-85. [Abstract] [Full-text]
108. CD4(+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 42(3): 269-76. [Abstract] [Full-text]
109. Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial.
     J Acquir Immune Defic Syndr, 42(3): 314-21. [Abstract] [Full-text]
110. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 42(3): 293-7. [Abstract] [Full-text]
111. The added value of a CD4 count to identify patients eligible for highly active antiretroviral therapy among HIV-positive adults in Cambodia.
     J Acquir Immune Defic Syndr, 42(3): 322-4. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.